Research reference
Glutathione Injection Dosage: What the Research Reports
Published by Peptara Labs · Updated · How we research and check our pages
Glutathione injection dosage has no established general-use protocol: the human research is thin, and the figures that do exist come from supervised clinical trials for specific conditions, not from a number anyone should copy at home.
The short answer
One controlled trial gives a clear intravenous protocol: glutathione 1,400 mg or placebo, three times a week for 4 weeks, in 21 randomized patients with Parkinson disease, where it was well tolerated but produced no significant difference in symptom scores (Hauser et al., Mov Disord 2009, PMID 19230029). That figure belongs to a supervised clinical trial for a neurological indication, and it does not carry across to anything else. For the use most people are searching about, skin lightening, a peer-reviewed review found no evidence that intravenous glutathione works and reported a national regulator warning against it (Sonthalia et al., 2016, PMID 27088927). There is also no US product label for an injectable glutathione product to read. This page reports what the literature says. It is not a dose for anyone.
General educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.
A clinic drip and a research vial are not the same product
Almost every confused answer on this topic comes from collapsing two different things into one word. Separate them first and the rest of the page reads cleanly.
The clinic
An in-office procedure, chosen and run by a clinician
An intravenous drip is administered on site, into a vein, by someone qualified to do it and present while it runs. The amount, the rate and the schedule are that clinician's decision for that patient, made with the ability to stop. In the published trial that setting is explicit: patients enrolled, randomized, monitored, and assessed on a rating scale (Hauser et al., Mov Disord 2009, PMID 19230029).
The research vial
Lyophilized material sold for laboratory research
A research vial is powder in glass with a certificate of analysis behind it. It is not a prepared intravenous product, it does not arrive with a procedure, and no figure from a supervised clinical trial describes it. What a certificate can tell you is identity, purity and what else was screened for, which is a different and much narrower question than what anyone should do with it.
Keeping those apart is what makes the numbers further down readable. A trial dose is a record of what a research team administered to enrolled patients. It is not a specification that travels with the molecule. For what Peptara publishes about the material it sells, including batch certificates, see the glutathione product page.
What the research reports, by route
Three published protocols, three different routes, three different questions. The Model column is the one to read first: one of these rows is an animal study, and the numbers in it are milligrams per kilogram of guinea pig.
| Route | Model | Protocol the study ran | What it measured | Source |
|---|---|---|---|---|
| Intravenous | Adults with Parkinson disease, 21 randomized | Glutathione 1,400 mg or placebo, three times a week for 4 weeks | Safety and tolerability, plus UPDRS scores. Well tolerated, no withdrawals for adverse events, no significant difference in UPDRS change between groups | Hauser et al., Mov Disord 2009, PMID 19230029 |
| Oral | Healthy female subjects, three-arm randomized trial | Reduced or oxidized glutathione at 250 mg per day, or placebo, for 12 weeks; earlier work cited at 500 mg per day | Melanin index, wrinkles, skin elasticity and biophysical properties, with blood safety monitoring. No serious adverse effects reported | Weschawalit et al., Clin Cosmet Investig Dermatol 2017, PMID 28490897 |
| Parenteral (intraperitoneal), animal only | Guinea pigs with UVB-induced hyperpigmentation | 10, 20 or 40 mg/kg body weight, three times a week for three weeks | Chromameter skin lightening, melanin granule counts, electron microscopy, plus liver, kidney and lung histology and blood chemistry | AlGhamdi et al., Dermatol Ther 2020, PMID 31885127 |
Notice what these rows do not do. They do not converge on a number, they were not run in the same population, and none of them tested the others' endpoint. The intravenous trial was a safety and tolerability pilot in patients with a movement disorder. The oral trial measured skin properties in healthy volunteers. The parenteral dose-response data are from guinea pigs. Averaging across them, or converting one route into another, is not something any of the three papers supports.
There is no injectable label to read
A reasonable instinct with any injectable is to go and read the product label, because a label carries an approved amount, a route and a set of warnings that somebody had to justify to a regulator. For glutathione injection in the United States, that document does not exist.
DailyMed is the National Library of Medicine database of product labels submitted to the FDA. A query for glutathione on 29 August 2026 returned 57 product labels, and not one of them is an injectable dosage form. What is there is liquids, creams, soaps, capsules, sprays, emulsions, tablets, kits, a lotion, a pellet, a patch and a powder, a large share of them homeopathic preparations or topical cosmetic products.
So when a page quotes label directions for injectable glutathione, it is not quoting a US product label, because there is not one to quote. That is a dated snapshot of a database that changes, and it is worth re-checking rather than treating as permanent. It is also the honest reason this page reports trial protocols instead: the trials are the only documented protocols that exist.
What the evidence says about the skin-lightening use
Most searches for a glutathione injection dose are really about skin lightening, so it is worth answering directly rather than leaving it implied. A review in the Indian Journal of Dermatology, Venereology and Leprology examined the evidence across all three routes. Its finding on the injected route was blunt: although the use of intravenous glutathione injections is popular, there is no evidence to prove its efficacy, and adverse effects caused by intravenous glutathione led the Food and Drug Administration of the Philippines to issue a public warning condemning its use for off-label indications such as skin lightening (Sonthalia et al., 2016, PMID 27088927).
The same review identified three randomized controlled trials supporting a skin-lightening effect and good safety profile for the topical and oral forms, while noting that duration of treatment, longevity of the effect and maintenance protocols all remain unanswered. A later oral trial, published in 2017, randomized healthy women to reduced glutathione, oxidized glutathione or placebo at 250 mg per day for 12 weeks and tracked melanin index, wrinkles and skin elasticity, with no serious adverse effects reported (Weschawalit et al., 2017, PMID 28490897).
Dose-response data on the parenteral route do exist, but they are animal data and should be read as such: glutathione was given intraperitoneally to guinea pigs at 10, 20 and 40 mg/kg three times a week for three weeks, with a dose-dependent lightening effect that was significant at the highest dose, and no toxic histological changes in the lung, kidney or liver specimens examined. The authors listed the guinea pig model and the short duration as limitations of their own study (AlGhamdi et al., Dermatol Ther 2020, PMID 31885127). Milligrams per kilogram of guinea pig is a finding about guinea pigs.
Concentration is arithmetic, not dosing
One genuinely useful thing can be said without going anywhere near a recommendation, and it is the part people most often get wrong. A vial label states a mass of lyophilized material in mg. Adding bacteriostatic water does not change that mass, it only changes how much liquid the same mass is spread through. Dividing mg in the vial by mL of water added gives mg per mL, and since a U-100 syringe reads 100 units per mL, the same vial yields entirely different unit readings depending on the volume used.
Which is why a units figure quoted with no concentration behind it carries no information at all, and why two people can follow the same unit number and be handling very different amounts of material. The peptide reconstitution calculator runs this conversion for any vial strength and any volume entered. It has no presets and no catalog list: every number it shows follows from what you type into it, which is the point.
Keep reading
The compound, the certificates, and the arithmetic
Glutathione
The product page: vial strength, certificates of analysis, and what ships.
Peptide reconstitution calculator
Turn a vial strength and a water volume into mg/mL and U-100 units.
Glutathione complete guide
Mechanism, the antioxidant role, routes, and storage in one place.
Peptide injection basics
What the terms mean before any number is attached to them.
How to read a COA
What each test on a certificate of analysis is actually reporting.
Are peptides legal
Research-use status, FDA standing, and why it varies by jurisdiction.
Glutathione injection dosage: FAQ
What glutathione injection dosage has been used in clinical research?
The clearest published intravenous protocol comes from a randomized, placebo-controlled, double-blind pilot trial in Parkinson disease: intravenous glutathione 1,400 mg or placebo, administered three times a week for 4 weeks, in 21 randomized subjects (Hauser et al., Mov Disord 2009, PMID 19230029). Glutathione was well tolerated with no withdrawals due to adverse events, and there were no significant differences between groups in Unified Parkinson Disease Rating Scale scores. That is a protocol a research team administered to its own enrolled patients under medical supervision for a neurological indication. It is reported here as what the trial did, and it is not a dose for anyone else, for any other purpose.
Is a clinic IV drip the same thing as a research vial?
No, and treating them as interchangeable is the single most common error in this topic. A clinic IV is a procedure: a clinician selects it, prepares it, administers it in-office through a vein, and is present while it runs. A research vial is lyophilized material sold for laboratory research use. It is not that product, it does not come with that procedure, and no dose from a supervised clinical setting transfers to it. The two share the word glutathione and almost nothing else that matters.
What does the labeling on injectable glutathione say?
There is no US labeling for an injectable glutathione product to read, which is itself the answer. A query of DailyMed, the National Library of Medicine database of FDA-submitted product labels, returned 57 glutathione product labels on 29 August 2026, and none of them is an injectable dosage form. The forms present are liquids, creams, soaps, capsules, sprays, emulsions, tablets, kits, a lotion, a pellet, a patch and a powder, many of them homeopathic or topical cosmetic products. So anyone quoting label directions for an injectable glutathione product is quoting something other than a US product label. That is a dated snapshot of a database that changes, not a permanent statement.
Does injected glutathione lighten skin?
A peer-reviewed review of the evidence concluded that although intravenous glutathione injections are popular for this purpose, there is no evidence to prove their efficacy, and that adverse effects from intravenous glutathione led the Food and Drug Administration of the Philippines to issue a public warning condemning its use for off-label indications such as skin lightening (Sonthalia et al., Indian J Dermatol Venereol Leprol 2016, PMID 27088927). The same review found three randomized controlled trials supporting topical and oral forms, and noted that duration of treatment, longevity of any effect and maintenance protocols all remain unanswered. Dose-response work on the parenteral route exists but is animal: glutathione at 10, 20 and 40 mg/kg was given intraperitoneally to guinea pigs three times a week for three weeks, with the effect described as dose-dependent and significant at the highest dose (AlGhamdi et al., Dermatol Ther 2020, PMID 31885127).
Why do oral and injected doses look so different?
Because they are answering different questions in different studies, not because one converts into the other. The oral randomized trial gave 250 mg per day of reduced or oxidized glutathione for 12 weeks and referenced earlier work at 500 mg per day (Weschawalit et al., Clin Cosmet Investig Dermatol 2017, PMID 28490897). The intravenous trial gave 1,400 mg three times weekly for a neurological indication in patients (Hauser et al., Mov Disord 2009, PMID 19230029). Different route, different population, different endpoint, different purpose. Placing the two numbers side by side and doing arithmetic between them is not something either paper supports.
How is a research vial concentration worked out?
That part is division, not dosing. A vial label states a mass of lyophilized material in mg, and adding bacteriostatic water never changes that mass. Dividing the mg in the vial by the mL of water added gives mg per mL, and because a U-100 syringe reads 100 units per mL, the same vial produces completely different unit readings depending on how much water went in. That is why a units figure quoted without the concentration behind it is meaningless. It is arithmetic for reading a label, and it says nothing about what anyone should draw.
References
- Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. "Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease." Movement Disorders. 2009;24(7):979-983. PMID: 19230029. doi:10.1002/mds.22401.
- Sonthalia S, Daulatabad D, Sarkar R. "Glutathione as a skin whitening agent: Facts, myths, evidence and controversies." Indian Journal of Dermatology, Venereology and Leprology. 2016;82(3):262-272. PMID: 27088927. doi:10.4103/0378-6323.179088.
- Weschawalit S, Thongthip S, Phutrakool P, Asawanonda P. "Glutathione and its antiaging and antimelanogenic effects." Clinical, Cosmetic and Investigational Dermatology. 2017;10:147-153. PMID: 28490897. doi:10.2147/CCID.S128339.
- AlGhamdi KM, Kumar A, Al-Rikabi AC, Mubarak M. "Safety and efficacy of parenteral glutathione as a promising skin lightening agent: A controlled assessor blinded pharmacohistologic and ultrastructural study in an animal model." Dermatologic Therapy. 2020;33(2):e13211. PMID: 31885127. doi:10.1111/dth.13211.
- DailyMed, National Library of Medicine. Product label search for glutathione, 57 results returned on 29 August 2026. https://dailymed.nlm.nih.gov/dailymed/
General educational information only, research-use framing, not medical advice. Every figure above is a protocol a named study administered to its own subjects or animals, reported as such. None of it is a recommendation. Consult a qualified professional before acting.